| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 3.5 | 2.3 |
| Profit before tax | 1.2 | 0.3 |
| Net income | 0.9 | 0.3 |
| EPS (diluted, $ a share) | $0.20 | $0.06 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +246.8% |
|---|---|
| Revenue, year on year | +54.3% |
| Operating margin | 31.7% |
10-Q filed with the SEC, NASDAQ: UG. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
United Guardian Inc: key numbers
- Share price
- $8.08Close, Nov 16
- Market cap
- $37.1M
- Shares outstanding
- 4.59MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Perfumes, Cosmetics & Other Toilet PreparationsSIC 2844
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from United Guardian Inc
All →United Guardian Financial Results
United-Guardian reported strong third quarter 2026 results with net sales increasing 54% to $3.5 million and net income surging 247% to $0.93 million. Growth was driven by a 187% increase in cosmetic ingredient sales and a 29% rise in pharmaceutical sales, specifically for its lead product Renacidin.
- Term
- Q3 2026
“I am very excited to report that our third quarter was exceptionally strong, with pharmaceuticals, personal care and medical lubricants all posting sales increases. Pharmaceutical sales grew 29% compared with the same period in 2025, driven primarily by Renacidin®, our most important pharmaceutical product.”
Donna Vigilante, President of United-Guardian
“I am very pleased with our performance for the first nine months of 2026. Our growth initiatives have produced encouraging results, and we plan to continue building on this progress.”
Donna Vigilante, President of United-Guardian